Project Grant T32CA285274
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$193K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $169,932 to The Trustees of Columbia University in the City of New York to advance proteomics technologies for cancer research. The grant aims to enhance the capabilities of the university's Proteomics and Macromolecular Crystallography Shared Resource (PMCSR) by introducing innovative methodologies such as automated deep proteomic profiling, immunopeptidomics, and cell surfaceome...
The National Cancer Institute (NCI) awarded a Project Grant of $253,405.00 on August 23, 2024 under the Cancer Research Manpower program (CFDA 93.398) to The Trustees of Columbia University in the City of New York to conduct research aimed at improving bacterial cancer therapeutics. The project summary indicates the research will focus on identifying the mechanisms by which bacteria, particularly E. coli, migrate to and grow within tumor tissue. This work aims to develop a better understanding...
The National Cancer Institute (NCI) awarded a $432,326 Project Grant (CFDA 93.398 Cancer Research Manpower) to The University of Texas Southwestern Medical Center to support the "Translational Cancer Biology (TCB) T32 Training Program". This 5-year program (9/1/2024 - 8/31/2029) provides training for 2 pre-doctoral and 4 post-doctoral trainees in cutting-edge areas of cancer research, with a focus on bridging basic science and clinical applications. The program aims to develop...
The National Cancer Institute (NCI) awarded a $560,297 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Icahn School of Medicine at Mount Sinai. The grant, with a project period from September 1, 2024 to August 31, 2029, will fund research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The research aims to determine the molecular drivers of the ONFSCS and their role in CRC progression and treatment resistance, as well as...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $716,314 to The Trustees of Columbia University in the City of New York to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal cancer. The key products and services to be delivered include: Utilizing immune-competent mouse models to develop and test highly efficacious FGFR2 biparatopic antibodies and antibody-drug conjugates, both alone and in...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), aims to develop enhanced cancer risk prediction models for underrepresented populations, particularly Black and Hispanic individuals. The $432,304 grant, awarded on January 3, 2025, will fund the development of novel data integration and machine learning methods to effectively leverage multi-source electronic health record (EHR) and biobank data. The...
The National Cancer Institute (NCI) awarded a $600,499 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Trustees of Columbia University in the City of New York to investigate microbial and host biomarkers in colorectal cancer oncogenesis. Specifically, the project aims to (I) explore the mechanistic and therapeutic role of amyloid-like FadA, an adhesin from the oral bacterium Fusobacterium nucleatum, in colorectal cancer, and (II) investigate the mechanistic and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $166,428 to The Leland Stanford Junior University to support a new T32 predoctoral training program focused on "Genetic and Environmental Basis of Cancer Risk and Disparities (GECARD)". The program aims to train the next generation of multi-disciplinary cancer researchers with expertise in unraveling the complex factors underlying cancer risk and disparities. Key aspects of the...
The $181,640 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the principal investigator's efforts to improve survival of patients with gastrointestinal malignancies, particularly colorectal and anal cancer. The award funds the evaluation of circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA) as predictive biomarkers for response to immunotherapy combinations in NCI-sponsored clinical trials. Specifically, the PI will analyze...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) provides $154,642 to the Sloan-Kettering Institute for Cancer Research to elucidate the evolving immunopeptidome of metastatic colorectal cancer. The award aims to systematically identify conserved intracellular targets derived from fetal-like gene expression programs in colorectal tumors that could serve as therapeutic interventions. Additionally, the project will...